Navigation Links
Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

Tamara Minko, professor in the Ernest Mario School of Pharmacy and Lorna Rodriguez, professor of obstetrics and gynecology at Rutgers Cancer Institute of New Jersey, say because there is not a good screening method for ovarian cancer, most women with the disease are not diagnosed until after it has metastasized to other organs and surgery and chemotherapy are not as effective.

"Once the ovarian cancer becomes drug resistant we cannot cure it," says Rodriguez an oncologist who provides treatment to ovarian cancer patients. "Circumventing the development of drug resistance is a reasonable approach and very much needed."

The main reason for advanced-stage ovarian cancer, they say, is an out of control protein CD44, which enables cancerous tumors to proliferate and become resistant to conventional drug treatments. The result: a five-year survival rate for patients with advanced-stage ovarian cancer that is only 30 percent.

In a new study published in Clinical Cancer Research, Minko and Rodriguez provide results of animal research in which the cancer is attacked at the genetic level by using small, inhibiting RNA molecules that directly target and decrease the excess CD44 protein in cancer cells while simultaneously treating patients with the anti-cancer drug paclitaxel. This allows cells within the cancerous tumors to be successfully treated even at an advanced stage.

"We expect that the proposed treatment will be especially effective in advanced stages of ovarian cancers, where there are many cancer stem cells in the tumors that resist conventional drug treatment," says Minko.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice. They then used a combination of chemotherapy and gene therapy to target the cancer cells directly in order to inhibit growth and prevent metastasis while sparing normal healthy cells. The treatment killed cancerous cells in the mice, shrunk their tumors and left them with fewer side effects.

Since the CD44 protein is expressed on the surface of many cancer stem cells, the approach developed by Rutgers scientists may help in the treatment of other types of cancers. The next step for ovarian cancer research would be to develop a drug for human consumption that could be used in clinical trials. This, they say, could lead to new pharmacological cancer treatments and increase the survival rate of the deadly disease.


Contact: Robin Lally
732-932-7084 x652
Rutgers University

Related medicine news :

1. Former Athlete Credits Sports for Surviving Horrible Car Accident and Lengthy Coma
2. Stage I NSCLC patients who receive radiation therapy are surviving longer
3. Floodmasters 5 Tips to Surviving the Next Hurricane Sandy
4. Too Much Sitting May Lower Odds of Surviving Colon Cancer
5. More Infants Surviving With Serious Heart Defects, Study Finds
6. ParentMagic Inc Releases Enhanced E-Book “Surviving Your Adolescents” Available in iBooks on iOS
7. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
8. Surviving a Tornado and Then Facing Homeowner Insurance Battles
9. Parent Magic Inc's "Surviving Your Adolescents" Wins Gold Award in National Parenting Publications Awards 2013
10. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
11. U.S. Panel Rejects Ovarian Cancer Screening
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: